FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Moyad

Research Profile

Objects

Disorders

Activities & Behaviors

Occupations

Complementary Therapies

Concepts & Ideas

Chemicals & Drugs

Procedures

Geographic Areas

United States

Co-author Network

Publications

TOP 3
Mark A Moyad; Kwangsung Park
What do most erectile dysfunction guidelines have in common? No evidence-based discussion or recommendation of heart-healthy lifestyle changes and/or Panax ginseng.
Mark A Moyad
Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Mark A Moyad
Heart healthy=prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti-oxidation mechanisms?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Moyad (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Mark A Moyad; Kwangsung Park
What do most erectile dysfunction guidelines have in common? No evidence-based discussion or recommendation of heart-healthy lifestyle changes and/or Panax ginseng.
Asian journal of andrology 2012;14(6):830-41.
2012: Mark A Moyad
Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
European urology 2012;61(3):623-4.
2012: Mark A Moyad
Heart healthy=prostate healthy: SELECT, the symbolic end of preventing prostate cancer via heart unhealthy and over anti-oxidation mechanisms?
Asian journal of andrology 2012;14(2):243-4.
2012: Mark A Moyad
The optimal male health diet and dietary supplement program.
The Urologic clinics of North America 2012;39(1):89-107.
2011: Mark A Moyad
Heart health = urologic health and heart unhealthy = urologic unhealthy: rapid review of lifestyle changes and dietary supplements.
The Urologic clinics of North America 2011;38(3):359-67.
2011: Mark A Moyad; Laurence H Klotz
Statin Clinical Trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement.
The Urologic clinics of North America 2011;38(3):325-31.
2011: Mark A Moyad; Kirk J Wojno
Molecular markers that can be utilized in diet and dietary supplement research.
The Urologic clinics of North America 2011;38(3):321-4.
2011: Mark A Moyad; Mack Roach
Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment.
The Urologic clinics of North America 2011;38(3):303-12.
2011: Mark A Moyad
Complementary and Alternative Medicine in Urology. Preface.
The Urologic clinics of North America 2011;38(3):xi-xii.
2010: Bulent Akduman; Daniel J Tandberg; Colin I O'Donnell; Alexa Hughes; Mark A Moyad; E David Crawford
Effect of Statins on Serum Prostate-specific Antigen Levels.
Urology 2010;76(5):1048-51.
2010: Mark A Moyad; Larry E Robinson; Edward T Zawada; Julie Kittelsrud; Ding-Geng Chen; Stuart Reeves; Susan Weaver
Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals.
Journal of alternative and complementary medicine (New York, N.Y.) 2010;16(2):213-8.
2010: Mark A Moyad
Can alternative medicine do better than placebo?: Does it even matter?
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2010;4(1):54-5.
2010: Mark A Moyad
Under-hyped and over-hyped drug-dietary supplement interactions and issues.
Urologic nursing 2010;30(1):85-7.
2009: Mark A Moyad
Conventional and alternative medical advice for cold and flu prevention: what should be recommended and what should be avoided?
Urologic nursing 2009;29(6):455-8.
2009: Mark A Moyad; Maile A Combs; Joshua E Baisley; Malkanthi Evans
Vitamin C with metabolites: additional analysis suggests favorable changes in oxalate.
Urologic nursing 2009;29(5):383-5.
2009: Mark A Moyad; Larry E Robinson; Julie M Kittelsrud; Stuart Reeves; Susan E Weaver; Aireen I Guzman; Mark E Bubak
Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial.
Advances in therapy 2009;26(8):795-804.
2009: Mark A Moyad; Maile A Combs; David C Crowley; Joshua E Baisley; Prachi Sharma; Angelica S Vrablic; Malkanthi Evans
Vitamin C with metabolites reduce oxalate levels compared to ascorbic acid: a preliminary and novel clinical urologic finding.
Urologic nursing 2009;29(2):95-102.
2009: Mark A Moyad
Vitamin D: a rapid review.
Dermatology nursing / Dermatology Nurses' Association 2009;21(1):25-30, 55.
2008: Mark A Moyad
Vitamin D: a rapid review.
Urologic nursing 2008;28(5):343-9, 384; quiz 350.
2008: Mark A Moyad; Maile A Combs; Angelica S Vrablic; Janet Velasquez; Benilda Turner; Samuel Bernal
Vitamin C metabolites, independent of smoking status, significantly enhance leukocyte, but not plasma ascorbate concentrations.
Advances in therapy 2008;25(10):995-1009.
2008: H Barton Grossman; Arnulf Stenzl; Mark A Moyad; Michael J Droller
Bladder cancer: chemoprevention, complementary approaches and budgetary considerations.
Scandinavian journal of urology and nephrology. Supplementum 2008;(218):213-33.
2008: Mark A Moyad; Franklin C Lowe
Educating patients about lifestyle modifications for prostate health.
The American journal of medicine 2008;121(8 Suppl 2):S34-42.
2008: Mark A Moyad
Conventional, complementary, and alternative options for seasonal allergies.
Urologic nursing 2008;28(3):227-8.
2008: Mark A Moyad; Larry E Robinson
Lessons learned from the 2007-2008 cold and flu season: what worked and what was worthless.
Urologic nursing 2008;28(2):146-8, 145.
2008: Mark A Moyad
Brewer's/baker's yeast (Saccharomyces cerevisiae) and preventive medicine: Part II.
Urologic nursing 2008;28(1):73-5.
2008: Mark A Moyad; Larry E Robinson; Edward T Zawada; Julie M Kittelsrud; Ding-Geng Chen; Stuart Reeves; Susan E Weaver
Effects of a modified yeast supplement on cold/flu symptoms.
Urologic nursing 2008;28(1):50-5.
2007: Mark A Moyad
Brewer's/baker's yeast (Saccharomyces cerevisiae) and preventive medicine: part I.
Urologic nursing 2007;27(6):560-1.
2007: Mark A Moyad; William Lusk; Lawrence R Schwartz
Alternative medicine utilization by African Americans and improving life expectancy: is there a correlation?
Urologic nursing 2007;27(5):449-50, 459.
2007: Mark A Moyad
What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
Urologic nursing 2007;27(3):256-7.
2007: Wendy Demark-Wahnefried; Mark A Moyad; Mark M Moyad
Dietary intervention in the management of prostate cancer.
Current opinion in urology 2007;17(3):168-74.
2007: Mark A Moyad; Gregory S Merrick
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI--The recent rise and fall of the HDL-boosting drug torceptrapib.
Urologic nursing 2007;27(2):169-73.
2007: Mark A Moyad; Gregory S Merrick
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Urologic nursing 2007;27(2):166-8.
2006: Mark A Moyad; Larry E Robinson
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part IV--is vitamin E phosphate or another unique type of this vitamin the last chance for these supplements?
Urologic nursing 2006;26(5):415-8.
2006: Mark A Moyad; Gregory S Merrick
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part III--A rapid review of FDA-approved cholesterol-lowering agents.
Urologic nursing 2006;26(4):330-2.
2006: Mark A Moyad; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Earnest G Butler; Zachariah A Allen; Edward Adamovich
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Urologic nursing 2006;26(4):298-303.
2006: Mark A Moyad; Gregory S Merrick
Cholesterol, cholesterol lowering agents/statins, and urologic disease: part II--do you know your Framingham Risk Score?
Urologic nursing 2006;26(3):227-9, 203.
2006: Mark A Moyad; Gregory S Merrick
Cholesterol, cholesterol lowering agents/statins, and urologic disease: part I - knowing your numbers.
Urologic nursing 2006;26(2):156-9.
2006: Mark A Moyad
Step-by-step lifestyle changes that can improve urologic health in men, part II: What do I tell my patients?
Primary care 2006;33(1):165-85, ix-x.
2006: Mark A Moyad
Step-by-step lifestyle changes that can improve urologic health in men, part I: What do I tell my patients?
Primary care 2006;33(1):139-63, ix.
2005: Mark A Moyad; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Brian Kurko; Edward Adamovich
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
Urology 2005;66(6):1150-4.
2005: Mark A Moyad
Abandoning isolated free PSA screenings for more comprehensive cardiovascular and cancer screening and education.
Urologic nursing 2005;25(2):137-41.
2005: Mark A Moyad
Fad diets and obesity--Part IV: Low-carbohydrate vs. low-fat diets.
Urologic nursing 2005;25(1):67-70.
2005: Mark A Moyad
Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients.
Urologic oncology 2005;23(1):56-64.
2005: Mark A Moyad; Gregory S Merrick
Statins and cholesterol lowering after a cancer diagnosis: why not?
Urologic oncology 2005;23(1):49-55.
2005: Mark A Moyad
An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II.
Urologic oncology 2005;23(1):36-48.
2005: Mark A Moyad
An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part I.
Urologic oncology 2005;23(1):28-35.
2005: Mark A Moyad
Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part II.
Current opinion in urology 2005;15(1):7-12.
2005: Mark A Moyad
Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I.
Current opinion in urology 2005;15(1):1-6.
2004: Sally P Weinrich; Julie Hudson Priest; Mark A Moyad; Martin C Weinrich
Intake of selected nutritional supplements by African-American men.
Urology 2004;64(6):1094-7.
2004: Mark A Moyad
Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease.
Urologic oncology 2004;22(6):485-9.
2004: Mark A Moyad
Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
Urologic oncology 2004;22(6):472-7.
2004: Mark A Moyad
Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
Urologic oncology 2004;22(6):466-71.
2004: Mark A Moyad
Fad diets and obesity--Part III: a rapid review of some of the more popular low-carbohydrate diets.
Urologic nursing 2004;24(5):442-5.
2004: Mark A Moyad
Fad diets and obesity--Part II: An introduction to the theory behind low-carbohydrate diets.
Urologic nursing 2004;24(3):210-3.
2004: Mark A Moyad
Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests.
The Urologic clinics of North America 2004;31(2):321-30.
2004: Mark A Moyad; Peter R Carroll
Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention?
The Urologic clinics of North America 2004;31(2):301-11.
2004: Mark A Moyad; Peter R Carroll
Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention?
The Urologic clinics of North America 2004;31(2):289-300.
2004: Mark A Moyad; James H Barada; Tom F Lue; John P Mulhall; Irwin Goldstein; Ahmed Fawzy
Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II.
The Urologic clinics of North America 2004;31(2):259-73.
2004: Mark A Moyad; James H Barada; Tom F Lue; John P Mulhall; Irwin Goldstein; Ahmed Fawzy
Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I.
The Urologic clinics of North America 2004;31(2):249-57.
2004: Mark A Moyad; Markus Sonnleithner
Prostate cancer and coronary heart disease: correlation or coincidence?
The Urologic clinics of North America 2004;31(2):207-12.
2004: Mark A Moyad
Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients?
The Urologic clinics of North America 2004;31(2):199-205.
2004: Mark A Moyad
Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part I: what do I tell my patients?
The Urologic clinics of North America 2004;31(2):195-8.
2004: Mark A Moyad
Fad diets and obesity--Part I: Measuring weight in a clinical setting.
Urologic nursing 2004;24(2):114-9.
2004: Mark A Moyad
Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem.
Urologic nursing 2004;24(1):49-52.
2003: Mark A Moyad
Lifestyle changes to prevent BPH: heart healthy = prostate healthy.
Urologic nursing 2003;23(6):439-41.
2003: Mark A Moyad
What do I tell my patients about drinking water and the risk of bladder cancer?
Urologic nursing 2003;23(5):371-7.
2003: Mark A Moyad
The potential benefits of dietary and/or supplemental calcium and vitamin D.
Urologic oncology 2003;21(5):384-91.
2003: Mark A Moyad
Osteoporosis: a rapid review of risk factors and screening methods.
Urologic oncology 2003;21(5):375-9.
2003: Mark A Moyad
Osteoporosis and prostate cancer.
Urologic oncology 2003;21(5):374.
2003: Mark A Moyad
Bladder cancer recurrence: Part II. What do I tell my patients about lifestyle changes and dietary supplements?
Current opinion in urology 2003;13(5):379-83.
2003: Mark A Moyad
Bladder cancer prevention. Part I: what do I tell my patients about lifestyle changes and dietary supplements?
Current opinion in urology 2003;13(5):363-78.
2003: Mark A Moyad
Calcium oxalate kidney stones: another reason to encourage moderate calcium intakes and other dietary changes.
Urologic nursing 2003;23(4):310-3.
2003: Jane Hokanson Hawks; Mark A Moyad
CAM: definition and classification overview.
Urologic nursing 2003;23(3):221-3.
2003: Mark A Moyad
The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II--rapid review of dietary supplements.
Current opinion in urology 2003;13(2):147-51.
2003: Mark A Moyad
The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy: part I--lifestyle changes.
Current opinion in urology 2003;13(2):137-45.
2003: Mark A Moyad
Osteoporosis. Part III--Not just for bone loss: potential benefits of calcium and vitamin D for overall general health.
Urologic nursing 2003;23(1):69-74.
2002: Mark A Moyad
Osteoporosis--Part II: Dietary and/or supplemental calcium and vitamin D.
Urologic nursing 2002;22(6):405-9.
2002: Mark A Moyad
Osteoporosis--Part I: Risk factors and screening.
Urologic nursing 2002;22(4):276-9.
2002: Mark A Moyad
Rules to follow before advising patients on dietary supplements/alternative medicine: Part II.
Urologic nursing 2002;22(3):173-7; quiz 178.
2002: Mark A Moyad
Rules to follow before advising patients on dietary supplements/alternative medicine: Part I.
Urologic nursing 2002;22(2):99-101, 104-10; quiz 111.
2002: Mark A Moyad
Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning a lesson from breast or other cancers, and the big picture.
Urology 2002;59(4 Suppl 1):51-62.
2002: Mark A Moyad
Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective.
Urology 2002;59(4 Suppl 1):41-50.
2002: Mark A Moyad
Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.
Urology 2002;59(4 Suppl 1):34-40.
2002: Mark A Moyad
Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women.
Urology 2002;59(4 Suppl 1):20-33.
2002: Mark A Moyad
Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?
Urology 2002;59(4 Suppl 1):9-19.
2002: Mark A Moyad; Kenneth J Pienta
Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk-an unmeasured and masked mediator of potential significance?
Urology 2002;59(4 Suppl 1):4-8.
2002: Mark A Moyad
Potential lifestyle and dietary supplement options for the prevention and postdiagnosis of bladder cancer.
The Urologic clinics of North America 2002;29(1):31-48, viii.
2002: Mark A Moyad
The placebo effect and randomized trials: analysis of alternative medicine.
The Urologic clinics of North America 2002;29(1):135-55, x.
2002: Mark A Moyad
The placebo effect and randomized trials: analysis of conventional medicine.
The Urologic clinics of North America 2002;29(1):125-33, ix-x.
2002: Mark A Moyad
Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?
The Urologic clinics of North America 2002;29(1):115-24, ix.
2002: Mark A Moyad
Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients?
The Urologic clinics of North America 2002;29(1):11-22, vii.
2001: Mark A Moyad
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Seminars in urologic oncology 2001;19(4):306-16.
2001: Mark A Moyad
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Seminars in urologic oncology 2001;19(4):294-305.
2001: Mark A Moyad
Review of potential risk factors for kidney (renal cell) cancer.
Seminars in urologic oncology 2001;19(4):280-93.
2001: Mark A Moyad
Obesity, interrelated mechanisms, and exposures and kidney cancer.
Seminars in urologic oncology 2001;19(4):270-9.
2001: Mark A Moyad
The prevalence and effectiveness of complementary and alternative medicine: what has been learned and what it may be telling us about our patients, ourselves, and conventional medical treatment.
Seminars in urologic oncology 2001;19(4):257-69.
2001: Mark A Moyad
Current methods used for defining, measuring, and treating obesity.
Seminars in urologic oncology 2001;19(4):247-56.
2001: Mark A Moyad
Results and lessons from clinical trials using dietary supplements for cancer: direct and indirect investigations.
Seminars in urologic oncology 2001;19(4):232-46.
2001: Mark A Moyad
Fat reduction to prevent prostate cancer: waiting for more evidence?
Current opinion in urology 2001;11(5):457-61.
1999: Mark A Moyad; Kenneth J Pienta; James E Montie
Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease.
Urology 1999;54(2):319-23; discussion 323-4.
1999: Mark A Moyad
Alternative therapies for advanced prostate cancer. What should I tell my patients?
The Urologic clinics of North America 1999;26(2):413-7, x.
1999: Mark A Moyad
Emphasizing and promoting overall health and nontraditional treatments after a prostate cancer diagnosis.
Seminars in urologic oncology 1999;17(2):119-24.
1999: Mark A Moyad; S Hathaway; H S Ni
Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research.
Seminars in urologic oncology 1999;17(2):103-10.
1999: Mark A Moyad
Soy, disease prevention, and prostate cancer.
Seminars in urologic oncology 1999;17(2):97-102.
1999: Mark A Moyad; S K Brumfield; Kenneth J Pienta
Vitamin E, alpha- and gamma-tocopherol, and prostate cancer.
Seminars in urologic oncology 1999;17(2):85-90.
1999: Mark A Moyad
Nontraditional treatments for localized prostate cancer: ten rules to know before talking to my patients.
Seminars in urologic oncology 1999;17(2):64-9.
1995: JE Oesterling; Mark A Moyad; G L Wright; G R Beck
An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.
Urology 1995;46(4):524-32.